{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:43:12Z","timestamp":1790707392427,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017577","name":"Zhejiang Province Basic Public Welfare Research Program","doi-asserted-by":"publisher","award":["LTGY24H160027"],"award-info":[{"award-number":["LTGY24H160027"]}],"id":[{"id":"10.13039\/501100017577","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.cbi.2025.111777","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:12:44Z","timestamp":1760145164000},"page":"111777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The novel selective HDAC1 inhibitor ZJH-1 exhibits potent antitumor activity in castration-resistant prostate cancer, potentially involving HSP90AA1"],"prefix":"10.1016","volume":"421","author":[{"given":"Yizhong","family":"Bao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aokang","family":"zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixiu","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjing","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2025.111777_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.cbi.2025.111777_bib2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41585-018-0020-2","article-title":"Translational models of prostate cancer bone metastasis","volume":"15","author":"Berish","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.cbi.2025.111777_bib3","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.eururo.2021.12.039","article-title":"Pre-existing castration-resistant prostate cancer-like cells in primary prostate cancer promote resistance to hormonal therapy","volume":"81","author":"Cheng","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.cbi.2025.111777_bib4","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.7150\/thno.92119","article-title":"A novel selenium analog of HDACi-based twin drug induces apoptosis and cell cycle arrest via CDC25A to improve prostate cancer therapy","volume":"14","author":"Shi","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.cbi.2025.111777_bib5","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cbi.2025.111777_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100962","article-title":"Current therapy and drug resistance in metastatic castration-resistant prostate cancer","volume":"68","author":"Cai","year":"2023","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.cbi.2025.111777_bib7","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in cancer development and therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.cbi.2025.111777_bib8","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/s12916-023-03094-0","article-title":"A new histone deacetylase inhibitor remodels the tumor microenvironment by deletion of polymorphonuclear myeloid-derived suppressor cells and sensitizes prostate cancer to immunotherapy","volume":"21","author":"Chen","year":"2023","journal-title":"BMC Med."},{"key":"10.1016\/j.cbi.2025.111777_bib9","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.bjc.6604199","article-title":"Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy","volume":"98","author":"Weichert","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cbi.2025.111777_bib10","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1365-2559.2011.03797.x","article-title":"The significance of strong histone deacetylase 1 expression in the progression of prostate cancer","volume":"58","author":"Song","year":"2011","journal-title":"Histopathology"},{"key":"10.1016\/j.cbi.2025.111777_bib11","first-page":"769","article-title":"Expression profile of class I histone deacetylases in human cancer tissues","volume":"18","author":"Nakagawa","year":"2007","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.cbi.2025.111777_bib12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.cbi.2025.111777_bib13","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/bjc.2011.13","article-title":"Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours","volume":"104","author":"Razak","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cbi.2025.111777_bib14","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1182\/blood.2023021671","article-title":"Staphylococcus aureus induces drug resistance in cancer T cells in sezary syndrome","volume":"143","author":"Vadivel","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.cbi.2025.111777_bib15","doi-asserted-by":"crossref","first-page":"7138","DOI":"10.1158\/1078-0432.CCR-08-0122","article-title":"A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer consortium study","volume":"14","author":"Luu","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cbi.2025.111777_bib16","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.apsb.2019.05.001","article-title":"Synergistic antitumor activity of artesunate and HDAC inhibitors through elevating heme synthesis via synergistic upregulation of ALAS1 expression","volume":"9","author":"Chen","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.cbi.2025.111777_bib17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/1568009622666220624090542","article-title":"Recent progress in histone deacetylase (HDAC) 1 inhibitors as anticancer agent","volume":"23","author":"Patel","year":"2022","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.cbi.2025.111777_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116315","article-title":"Discovery of novel itaconimide-based derivatives as potent HDAC inhibitors for the efficient treatment of prostate cancer","volume":"269","author":"Jiang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111777_bib19","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.canlet.2020.05.008","article-title":"The novel dual BET\/HDAC inhibitor TW09 mediates cell death by mitochondrial apoptosis in rhabdomyosarcoma cells","volume":"486","author":"Laszig","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.cbi.2025.111777_bib20","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1038\/emboj.2010.281","article-title":"HDAC1, a novel marker for benign teratomas","volume":"29","author":"Simboeck","year":"2010","journal-title":"EMBO J."},{"key":"10.1016\/j.cbi.2025.111777_bib21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.yexmp.2015.03.024","article-title":"HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer","volume":"98","author":"Burdelski","year":"2015","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.cbi.2025.111777_bib22","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4062\/biomolther.2015.026","article-title":"A new histone deacetylase inhibitor, MHY219, inhibits the migration of human prostate cancer cells via HDAC1","volume":"23","author":"De","year":"2015","journal-title":"Biomol Ther (Seoul)"},{"key":"10.1016\/j.cbi.2025.111777_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19092560","article-title":"The HSP90 family: structure, regulation, function, and implications in health and disease","volume":"19","author":"Hoter","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cbi.2025.111777_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/and.14376","article-title":"Advances in the role of heat shock protein 90 in prostate cancer","volume":"54","author":"Fu","year":"2022","journal-title":"Andrologia"},{"key":"10.1016\/j.cbi.2025.111777_bib25","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1186\/1471-2407-11-468","article-title":"Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells","volume":"11","author":"Eskew","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cbi.2025.111777_bib26","first-page":"211","article-title":"Hsp90: still a viable target in prostate cancer","volume":"1835","author":"Centenera","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.cbi.2025.111777_bib27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.gene.2015.06.018","article-title":"Regulation and function of the human HSP90AA1 gene","volume":"570","author":"Zuehlke","year":"2015","journal-title":"Gene"},{"key":"10.1016\/j.cbi.2025.111777_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11033-012-1930-3","article-title":"Regulation of survival and chemoresistance by HSP90AA1 in ovarian cancer SKOV3 cells","volume":"40","author":"Chu","year":"2013","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.cbi.2025.111777_bib29","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1634\/theoncologist.2010-0379","article-title":"Losses of chromosome 5q and 14q are associated with favorable clinical outcome of patients with gastric cancer","volume":"17","author":"Buffart","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.cbi.2025.111777_bib30","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1074\/jbc.M208230200","article-title":"Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines","volume":"278","author":"Chen","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cbi.2025.111777_bib31","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1158\/0008-5472.CAN-15-0088","article-title":"AIP1 expression in tumor niche suppresses tumor progression and metastasis","volume":"75","author":"Ji","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.cbi.2025.111777_bib32","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1186\/s12885-022-09596-z","article-title":"DAB2IP down-regulates HSP90AA1 to inhibit the malignant biological behaviors of colorectal cancer","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cbi.2025.111777_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104652","article-title":"Design, synthesis and antitumor activity evaluation of novel HDAC inhibitors with tetrahydrobenzothiazole as the skeleton","volume":"108","author":"Sun","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.cbi.2025.111777_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.archger.2024.105739","article-title":"A novel histone deacetylase inhibitor protects the blood-brain barrier by regulating NF-kappaB and Nrf2 signaling pathways in OGD\/R injury","volume":"131","author":"Ling","year":"2025","journal-title":"Arch. Gerontol. Geriatr."},{"key":"10.1016\/j.cbi.2025.111777_bib35","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nprot.2016.006","article-title":"Organoid culture systems for prostate epithelial and cancer tissue","volume":"11","author":"Drost","year":"2016","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.cbi.2025.111777_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117792","article-title":"Enhancing anti-cancer capacity: novel class I\/II HDAC inhibitors modulate EMT, cell cycle, and apoptosis pathways","volume":"109","author":"Lee","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111777_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116129","article-title":"HDAC-Targeting epigenetic modulators for cancer immunotherapy","volume":"265","author":"Cheng","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111777_bib38","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.canlet.2009.02.027","article-title":"Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer","volume":"280","author":"Botrugno","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.cbi.2025.111777_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cbi.2025.111777_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105695","article-title":"Histone deacetylase 2 selective inhibitors: a versatile therapeutic strategy as next generation drug target in cancer therapy","volume":"170","author":"Shetty","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.cbi.2025.111777_bib41","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1111\/bcp.14889","article-title":"Recent developments of HDAC inhibitors: emerging indications and novel molecules","volume":"87","author":"Bondarev","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.cbi.2025.111777_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117185","article-title":"Synthetic approaches and clinical applications of representative HDAC inhibitors for cancer therapy: a review","volume":"283","author":"Lv","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.cbi.2025.111777_bib43","article-title":"Mechanisms of HDACs in cancer development","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cbi.2025.111777_bib44","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.7150\/thno.96027","article-title":"Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development","volume":"14","author":"Xiang","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.cbi.2025.111777_bib45","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41419-023-05763-7","article-title":"Aberrant cyclin D1 splicing in cancer: from molecular mechanism to therapeutic modulation","volume":"14","author":"Wang","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cbi.2025.111777_bib46","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1002\/cncr.34974","article-title":"Recent histone deacetylase inhibitors in cancer therapy","volume":"129","author":"Parveen","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.cbi.2025.111777_bib47","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4291\/wjgp.v3.i3.71","article-title":"Molecular signaling mechanisms of apoptosis in hereditary non-polyposis colorectal cancer","volume":"3","author":"Hassen","year":"2012","journal-title":"World J. Gastrointest. Pathophysiol."},{"key":"10.1016\/j.cbi.2025.111777_bib48","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2174\/0115748928251754230922095544","article-title":"Matrix Metalloproteinase-2 (MMP-2): as an essential factor in cancer progression","volume":"20","author":"Reddy","year":"2025","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"10.1016\/j.cbi.2025.111777_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/biom15010035","article-title":"Targeting invasion: the role of MMP-2 and MMP-9 inhibition in colorectal cancer therapy","volume":"15","author":"Shoari","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.cbi.2025.111777_bib50","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1053\/j.gastro.2009.04.004","article-title":"E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL\/HDAC1\/HDAC2 repressor complex","volume":"137","author":"von Burstin","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cbi.2025.111777_bib51","article-title":"A novel class I HDAC inhibitor, AW01178, inhibits epithelial-mesenchymal transition and metastasis of breast cancer","volume":"25","author":"Liu","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cbi.2025.111777_bib52","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/pros.23837","article-title":"The metastasis suppressor CD82\/KAI1 represses the TGF-Beta (1) and wnt signalings inducing epithelial-to-mesenchymal transition linked to invasiveness of prostate cancer cells","volume":"79","author":"Lee","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.cbi.2025.111777_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/life12101489","article-title":"Heat shock protein 70 and 90 family in prostate cancer","volume":"12","author":"Fu","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.cbi.2025.111777_bib54","article-title":"Exploring the therapeutic mechanism of curcumin in prostate cancer using network pharmacology and molecular docking","volume":"10","author":"Li","year":"2024","journal-title":"Heliyon"}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279725004077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279725004077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T05:04:58Z","timestamp":1780722298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279725004077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":54,"alternative-id":["S0009279725004077"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2025.111777","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The novel selective HDAC1 inhibitor ZJH-1 exhibits potent antitumor activity in castration-resistant prostate cancer, potentially involving HSP90AA1","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2025.111777","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111777"}}